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ofOBJECTIVES This study sought to evaluate: 1) the effect of impaired renal function on long-term clinical outcomes
in women undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES); and 2) the safety and
efﬁcacy of new-generation compared with early-generation DES in women with chronic kidney disease (CKD).
BACKGROUND The prevalence and effect of CKD in women undergoing PCI with DES is unclear.
METHODS We pooled patient-level data for women enrolled in 26 randomized trials. The study population was
categorized by creatinine clearance (CrCl) <45 ml/min, 45 to 59 ml/min, and $60 ml/min. The primary endpoint was the
3-year rate of major adverse cardiovascular events (MACE). Participants for whom baseline creatinine was missing were
excluded from the analysis.
RESULTS Of 4,217 women included in the pooled cohort treated with DES and for whom serum creatinine was available,
603 (14%) had a CrCl <45 ml/min, 811 (19%) had a CrCl 45 to 59 ml/min, and 2,803 (66%) had a CrCl $60 ml/min.
A signiﬁcant stepwise gradient in risk for MACE was observed with worsening renal function (26.6% vs. 15.8% vs. 12.9%;
p < 0.01). Following multivariable adjustment, CrCl <45 ml/min was independently associated with a higher risk of MACE
(adjusted hazard ratio: 1.56; 95% conﬁdence interval: 1.23 to 1.98) and all-cause mortality (adjusted hazard ratio: 2.67; 95%
conﬁdence interval: 1.85 to 3.85). Compared with older-generation DES, the use of newer-generation DES was associated
with a reduction in the risk of cardiac death, myocardial infarction, or stent thrombosis in women with CKD. The effect of
new-generation DES on outcomes was uniform, between women with or without CKD, without evidence of interaction.
CONCLUSIONS Among women undergoing PCI with DES, CKD is a common comorbidity associated with a strong and
independent risk for MACE that is durable over 3 years. The beneﬁts of newer-generation DES are uniform in women with
or without CKD. (J Am Coll Cardiol Intv 2016;9:28–38) © 2016 by the American College of Cardiology Foundation.m *The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York City, New
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CAD = coronary artery disease
CKD = chronic kidney disease
CrCl = creatinine clearance
DES = drug-eluting stent(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
RCT = randomized controlled
trial
ST = stent thrombosisA mong patients with coronary artery disease(CAD) undergoing percutaneous coronaryintervention (PCI), the presence of even
mild chronic kidney disease (CKD) is associated with
a strong and independent risk for adverse cardiovas-
cular events (1–4). Moreover, several studies suggest
that the safety and efﬁcacy of drug-eluting stent
(DES) implantation may be attenuated in the setting
of renal dysfunction (5,6). Possible mechanistic link-
ages between CKD and cardiovascular risk after PCI
include accelerated atherosclerosis within and
outside of the stented vascular segment and a pro-
inﬂammatory milieu (7). Moreover, enhanced bloodSEE PAGE 39
TLR = target lesion
revascularizationthrombogenicity related to renal dysfunction in-
creases risk for myocardial infarction (MI) and stent
thrombosis (ST) in patients with CKD (7–9).
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ity among women undergoing PCI and may be a
contributor to post-PCI risk in female patientszzInstitut Lorrain du Coeur et des Vaisseaux (ILCV) University Hospi
xxDepartment of Cardiology, Maasstad Hospital, Rotterdam, the Netherla
{{Thoraxcentrum Twente, Enschede, the Netherlands; ##Department of Card
Denmark; ***Department of Cardiology, University Hospital Basel, Basel,
University Graduate School of Medicine, Kyoto, Japan; zzzDepartment of C
London, United Kingdom; xxxDepartment of Cardiology, Hoag Memorial
kkkDepartment of Cardiology, Ohio State University Medical Center, Columb
and Interventions, Washington, DC; ###Department of Cardiology, Seoul Na
****Herzzentrum, Munich, Germany; and the yyyyInterventional Cardiology U
Gender Data Forum was sponsored by the Women in Innovation Initiative
Interventions. Dr. Stefanini has received speaker fees from Abbott Vascular
cines Company. Dr. Steg has received honorarium from Medtronic as a ste
received research grants from Sanoﬁ and Servier; has received funding from
Bristol-Myers Squibb, Daiichi-Sankyo-Lilly, GlaxoSmithKline, Medtronic, Me
The Medicines Company; and is a stockholder in Aterovax. Dr. Windecker ha
Abbott, Biotronik, Boston Scientiﬁc, Biosensors, Cordis, Medtronic, and S
AstraZeneca, Eli Lilly, Abbott, Biotronik, Biosensor, Boston Scientiﬁc, Medtro
received institutional research grants from Boston, Medtronic, Abbott, Teru
trials by Boston, Medtronic, Abbott, Terumo, and Biosensors; is a nonexec
Partners, Cardio3BioSciences, and Genae; and fees or honoraria on his be
Biosensors go to the Cardiovascular Center Aalst. Dr. Valgimigli has received
grants from Merck, Iroko, Eli Lilly, and Medtronic; honoraria for advisory
Eli Lilly, Daiichi Sankyo, St. Jude, and Abbott Vascular; and honoraria for
Devices, and Terumo. Dr. Smits has received institutional research grants an
Terumo. Dr. Kandzari has received research or grant support from Medtron
consulting honoraria fromMedtronic, Biotronik, and Boston Scientiﬁc. Dr. Vo
fees or travel expenses from Abbott Vascular, AstraZeneca, Biotronik, Boston
and his research department Thoraxcentrum Twente has received educatio
Zeneca, Biotronik, Boston Scientiﬁc, and Medtronic. Dr. Galatius has receive
Biotronik; and has received advisory board honorarium from Eli Lilly and
fellowship from Abbott Vascular; and has received speakers honoraria from
research grant support from The Medicines Company, AstraZeneca, Bristol-
received consulting fees from Abbott Vascular, AstraZeneca, Bayer, Boston
ceuticals, Maya Medical, Merck, Osprey Medical Inc., Regado Biosciences, W
on the scientiﬁc advisory board of Abbott Laboratories, Boston Scientiﬁc C
Medicines Company, and Sanoﬁ. All other authors have reported that they h
paper to disclose. The ﬁrst 2 authors contributed equally to this work.
Manuscript received May 11, 2015; revised manuscript received August 5, 20(4,10,11). However, data on clinical out-
comes associated with DES implantation in
women with CKD are scarce as a result of
their restricted inclusion in randomized
controlled trials (RCTs).
In 2011, the Food and Drug Administra-
tion issued guidance for assessing sex dis-
parities in RCTs evaluating medical devices
(12). In response, the Society for Cardio-
vascular Angiography and Interventions’
Women in Innovation Initiative convened
the Gender Data Forum to discuss the out-
comes of DES in women, leading to the
performance of an individual patient-level
data pooled analysis from available ran-
domized trials of DES. The safety and efﬁcacy of
DES in women have been previously reported (13).
Accordingly, we sought to evaluate, by pooling
patient-level data from RCTs, the prognostic effect
of various degrees of impaired renal function in
women undergoing PCI with DES and the safety andtal Nancy—Brabois Vandoeuvre-lès-Nancy France;
nds; kkPiedmont Heart Institute, Atlanta, Georgia;
iology, Bispebjerg University Hospital, Copenhagen,
Switzerland; yyyDepartment of Cardiology, Kyoto
ardiology, Imperial College Healthcare NHS Trust,
Hospital Presbyterian, Newport Beach, California;
us, Ohio; {{{Society of Cardiovascular Angiography
tional University Main Hospital, Seoul, South Korea;
nit, San Raffaele Scientiﬁc Institute, Milan, Italy. The
of the Society of Cardiovascular Angiography and
, AstraZeneca, Biosensors, Biotronik, and The Medi-
ering committee member in the PROTECT trial; has
Amarin, AstraZeneca, Bayer, Boehringer Ingelheim,
rck, Novartis, Pﬁzer, Regeneron, Sanoﬁ, Servier, and
s received research contracts to the institution from
t. Jude; and has received speakers honoraria from
nic, Edwards Lifesciences, and Bayer. Dr. Wijns has
mo, and Biosensors; is an investigator for sponsored
utive board member and shareholder of Argonauts
half from Boston, Medtronic, Abbott, Terumo, and
honoraria for lectures or advisory board and research
board and lectures from The Medicines Company,
lectures from Cordis, Carbostent and Implantable
d speakers fees from Abbott Vascular, St. Jude, and
ic, Abbott, and Boston Scientiﬁc; and has received
n Birgelen is a consultant to and has received lecture
Scientiﬁc, Medtronic, and Merck Sharp and Dohme;
nal or research grants from Abbott Vascular, Astra-
d grant support from St. Jude, Abbott, Terumo, and
Servier. Dr. Mikhail has received an interventional
AstraZeneca. Dr. Mehran has received institutional
Myers Squibb, Sanoﬁ, Lilly, and Daiichi Sankyo; has
Scientiﬁc, CSL Behring, Covidien, Janssen Pharma-
atermark Research Partners, and Sanoﬁ; and serves
orporation, Covidien, Janssen Pharmaceuticals, The
ave no relationships relevant to the contents of this
15, accepted September 10, 2015.
Baber et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 1 , 2 0 1 6
Effect of CKD in Women Undergoing PCI With DES J A N U A R Y 1 1 , 2 0 1 6 : 2 8 – 3 8
30efﬁcacy proﬁle of new-generation compared with
early-generation DES in women with CKD.
METHODS
STUDY POPULATION. The rationale of the present
patient-level pooled database, list of trials, analytic
strategies, and pre-speciﬁed endpoints have been
previously reported (13). Brieﬂy, female participants
from 26 RCTs were pooled: RAVEL (The Initial
Double-Blind Drug-Eluting Stent vs Bare-Metal Stent
Study) (14), SIRIUS (Study of Sirolimus-Coated BX
VELOCITY Balloon-Expandable Stent in Treatment of
de Novo Native Coronary Artery Lesions) (15), E-
SIRIUS (The Study of the BX VELOCITY Stent In
Patients With De Novo Coronary Artery Lesions) (16),
C-SIRIUS (The Study of the BX Velocity Stent in the
Treatment of De Novo Artery Lesions) (17), TAXUS-I
(Randomized, Double-Blind Trial on a Slow-Release
Paclitaxel-Eluting Stent for De Novo Coronary
Lesions) (18), TAXUS-II SR (A Randomized Study to
Assess the Effectiveness of Slow- and Moderate-
Release Polymer-Based Paclitaxel-Eluting Stents for
De Novo Coronary Artery Lesions) (19), TAXUS-IV
(Treatment of De Novo Coronary Disease Using a
Single Paclitaxel-Eluting Stent) (20), TAXUS-V (A
Randomized, Double-blind Trial to Assess TAXUS
Paclitaxel-Eluting Coronary Stents, SR Formulation,FIGURE 1 Study Population Flow Diagram
BMS ¼ bare-metal stent(s); CrCl ¼ creatinine clearance; DES ¼ drug-eluin the Treatment of De Novo Coronary Lesions)
(21), SIRTAX (Sirolimus-Eluting Versus Paclitaxel-
Eluting Stents for Coronary Revascularization) (22),
ENDEAVOR II (Randomized Controlled Trial to Eval-
uate the Safety and Efﬁcacy of the Medtronic AVE
ABT-578 Eluting Driver Coronary Stent in De Novo
Native Coronary Artery Lesions) (23), ENDEAVOR III
(A Randomized Controlled Trial of the Medtronic
Endeavor Drug [ABT-578] Eluting Coronary Stent
System Versus the Cypher Sirolimus-Eluting Coro-
nary Stent System in De Novo Native Coronary Artery
Lesions) (24), ENDEAVOR-IV (Randomized Compari-
son of Zotarolimus-Eluting and Paclitaxel-Eluting
Stents in Patients with Coronary Artery Disease) (25),
SPIRIT II (A Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System in the
Treatment of Patients With de Novo Native Coronary
Artery Lesions) (26), SPIRIT III (A Clinical Evaluation
of the Investigational Device XIENCE V Everolimus
Eluting Coronary Stent System in the Treatment of
Subjects With de Novo Native Coronary Artery Le-
sions) (27), SPIRIT IV (Clinical Evaluation of the
XIENCE V Everolimus Eluting Coronary Stent System
in the Treatment of Subjects With de Novo Native
Coronary Artery Lesions) (28), BASKET-PROVE
(Evaluation of Late Clinical Events After Drug-
eluting Versus Bare-metal Stents in Patients at Risk:
BAsel Stent Kosten Effektivitäts Trial - PROspectiveting stent(s); Gen ¼ generation; RCT ¼ randomized controlled trial.
TABLE 1 Baseline Clinical and Angiographic Characteristics
CrCl <45 ml/min
(n ¼ 603)
CrCl 45–59 ml/min
(n ¼ 811)
CrCl $60 ml/min
(n ¼ 2,803)
p
Value
Age, yrs 76.7  8.2 73.8  7.6 64.0  9.7 0.01
BMI, kg/m2 24.1  4.5 25.8  4.4 29.2  5.7 <0.01
Risk factors
Diabetes mellitus 222 (36.8) 246 (30.3) 981 (35) 0.01
IDDM 84 (37.8) 74 (30.1) 307 (31.3) 0.12
Arterial hypertension 517 (85.7) 658 (81.1) 2,058 (73.4) <0.01
Hypercholesterolemia 390 (64.7) 566 (69.8) 1,948 (69.5) 0.06
Smoking 114 (19.0) 214 (26.4) 1,106 (39.5) <0.01
Family history of CAD 123 (21.8) 230 (29.6) 1,018 (37.6) <0.01
Clinical history
Previous MI 145 (24.0) 178 (21.9) 541 (19.3) <0.01
Previous PCI 171 (28.4) 184 (22.7) 517 (18.5) <0.01
Previous CABG 45 (7.5) 54 (6.7) 122 (4.4) <0.01
LVEF, % 53.9  16.7 54.6  18.7 53.2  21.9 0.31
Multivessel disease 243 (40.0) 241 (30.0) 664 (23.7) <0.01
Angiographic characteristics
Number of lesions treated 1.3  0.6 1.3  0.6 1.3  0.6 0.12
Number of stents implanted 1.6  0.9 1.6  0.9 1.3  0.6 0.07
Mean stent diameter, mm 2.9  0.4 2.9  0.4 3.0  0.4 <0.01
Total stent length, mm 31.1  21.4 30.8  20.0 29.3  19.5 <0.01
Type B2/C lesion 429 (73.1) 515 (65.3) 1,644 (59.7) <0.01
Moderate/severe calciﬁcations 170 (33.5) 237 (32.9) 656 (25.1) <0.01
Bifurcation lesion 60 (22.2) 53 (18.6) 201 (22.6) 0.35
Type of stent implanted <0.01
Early-generation DES 322 (53.4) 402 (49.6) 1,361 (48.6)
New-generation DES 281 (46.6) 409 (50.4) 1,442 (51.4)
Values are mean  SD or n (%).
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; DES ¼ drug-
eluting stent(s); IDDM ¼ insulin-dependent diabetes mellitus; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-
segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; SA ¼ stable angina; STEMI ¼
ST-segment elevation myocardial infarction; UA ¼ unstable angina.
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31Validation Examination Part II) (29), COMPARE I
(A Randomized Controlled Trial of Everolimus-
eluting Stents and Paclitaxel-eluting Stents for Coro-
nary Revascularization in Daily Practice) (30),
COMPARE II (Comparison of the Everolimus Eluting
With the Biolimus A9 Eluting Stent) (31), EXCELLENT
(The Efﬁcacy of Xience/Promus Versus Cypher to
Reduce Late Loss After Stenting) (11), RESET (REal
Safety and Efﬁcacy of 3-month dual antiplatelet
Therapy following Endeavor zotarolimus-eluting
stent implantation) (32), RESOLUTE AC (Random-
ized, Two-Arm, Non-inferiority Study Comparing
Endeavor-Resolute Stent With Abbot Xience-V Stent)
(33), TWENTE (The Real-World Endeavor Resolute
Versus XIENCE V Drug-Eluting Stent Study in
Twente) (34), LEADERS (A Randomized Comparison
of a Biolimus-Eluting Stent With a Sirolimus-Eluting
Stent for Percutaneous Coronary Intervention) (35),
ISAR TEST 4 (Prospective, Randomized Trial of
3-limus Agent-eluting Stents With Different Polymer
Coatings) (36), PRODIGY (PROlonging Dual Anti-
platelet Treatment In Patients With Coronary Artery
Disease After Graded Stent-induced Intimal Hyper-
plasia studY) (37), and PROTECT (Patient Related
OuTcomes With Endeavor Versus Cypher Stenting
Trial) (38). Characteristics of the RCTs included in the
present study are summarized in Online Table 1. All of
the included randomized controlled trials were per-
formed between 2000 and 2013.
According to baseline creatinine clearance (CrCl),
the study population was stratiﬁed by: 1) CrCl <45
ml/min, 2) CrCl between 45 and 59 ml/min, and 3)
CrCl $60 ml/min (Figure 1). Women receiving bare-
metal stents were excluded from the present
analysis. Participants whose baseline creatinine was
not available were also excluded from the analysis.
All trials included in our analysis complied with
the provisions of the Declaration of Helsinki, and the
study protocols were approved by the institutional
review board at each study center. All patients pro-
vided written informed consent for participation in
each study.
DRUG-ELUTING STENTS. The following DES have
been included in the present analysis: sirolimus-
eluting stents (Cypher and Cordis, Johnson & John-
son, Miami Lakes, Florida), paclitaxel-eluting
stents (Taxus, Boston Scientiﬁc, Natick, Massachu-
setts), everolimus-eluting stents (Xience, Abbott
Vascular, Santa Clara, California; Promus, Boston
Scientiﬁc), zotarolimus-eluting stents (Endeavor,
Medtronic, Santa Rosa, California; Resolute, Med-
tronic), biolimus-eluting stents with biodegradable
polymer coating (Biomatrix, Biosensors, NewportBeach, California; Nobori, Terumo, Tokyo, Japan), and
sirolimus-eluting stents with biodegradable polymer
coating (Yukon, Translumina, Hechingen, Germany).
Coronary stents used among trials were classiﬁed
as early-generation DES (including sirolimus- and
paclitaxel-eluting stents) and new-generation DES
(including everolimus-eluting stents, zotarolimus-
eluting stents with durable polymer, and biolimus-
and sirolimus-eluting stents with biodegradable
polymer).
ENDPOINTS. We evaluated the effect of impaired
renal function on 3-year risk of major adverse cardiac
events (MACE) deﬁned as the composite of all-cause
death, MI, target lesion revascularization (TLR), or
ST. Subsequently, we evaluated the effect of new-
generation DES (versus early-generation DES) on the
risk of device-oriented safety endpoints comprising
cardiac death, MI, or ST. The clinical endpoint deﬁ-
nitions used across trials are shown in Online Table 2.
FUNDING SOURCE. No funding source was available
for the gathering of these data, statistical analyses, or
FIGURE 2 3-Year Adverse Events According to Baseline Renal Function in Women Undergoing PCI With DES
Kaplan-Meier survival curves for major adverse cardiac events (A) and death (B) at 3 years in women according to baseline renal function.
The p values are from log-rank test. CrCl ¼ creatinine clearance; MACE ¼ major adverse cardiac event(s).
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TABLE 2 Adjusted 3-Year Clinical Outcomes According to Renal Function
CrCl $60 ml/min
(Reference Group)
CrCl 45–59
ml/min
CrCl <45
ml/min
p Value
for Trend
Death 1.00 1.12 (0.77–1.64) 2.67 (1.85–3.85) <0.01
Cardiac death 1.00 1.40 (0.84–2.35) 2.75 (1.65–4.61) <0.01
Myocardial infarction 1.00 0.95 (0.66–1.38) 1.33 (0.90–1.97) <0.01
TLR 1.00 0.79 (0.54–1.15) 0.95 (0.62–1.45) 0.56
Deﬁnite or probable ST 1.00 0.91 (0.42–1.99) 1.54 (0.70–3.39) 0.05
Death or MI 1.00 1.01 (0.76–1.33) 1.91 (1.44–2.52) <0.01
Death, MI, or ST 1.00 0.98 (0.74–1.29) 1.85 (1.40–2.44) <0.01
MACE 1.00 0.94 (0.75–1.19) 1.56 (1.23–1.98) <0.01
Values are hazard ratio (95% conﬁdence interval) unless otherwise indicated.
MACE ¼ major adverse cardiac event(s); ST ¼ stent thrombosis; TLR ¼ target lesion revascularization; other
abbreviations as in Table 1.
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33drafting of this report. The collaborative nature of the
present investigation initiative has been reported
previously (14). All of the contacted principal in-
vestigators and device manufacturers shared indi-
vidual patient data for female patients enrolled in
randomized controlled trials evaluating the safety
and efﬁcacy of different types of DES.
STATISTICAL ANALYSIS. All patient-level data were
aggregated and combined as 1 dataset using pre-
speciﬁed extraction sheet. Baseline clinical, de-
mographic, and procedural characteristics of CKD
groups were compared using linear regression for
continuous variables and chi-square tests for cate-
gorical variables. Cumulative event rates were
calculated with the Kaplan-Meier method and
compared between groups using the log-rank test. For
these analyses, the total follow-up was deﬁned as the
time from index procedure until death, last follow-up
date, or 3 years, whichever came ﬁrst. The median
follow-up time was 3 years in patients with CrCl $60
ml/min and between 45 and 59 ml/min, and was
2 years in those with CrCl <45 ml/min. The indepen-
dent associations between CKD severity and stent
generation and outcomes were assessed with the Cox
proportional hazards models that included a frailty
term (g) to assess random effects in the trials (39,40).
Frailties are the unmeasured factors that affect trial-
speciﬁc baseline risk and are distributed as g
random variables with a mean of 1 and variance q. The
variance parameter is interpreted as a metric of het-
erogeneity in baseline risk between trials. In the
analysis evaluating the effect of renal function on
outcomes, CrCl >60 ml/min served as the referent
category. For the DES-level analysis, older-generation
DES served as the referent category. As median
follow-up time differed signiﬁcantly across stent
generations (2 and 3 years among those receiving
new- and older-generation DES, respectively),
comparative analyses between DES groups were
censored at 2 years. Stent group, age, and baseline
variables showing signiﬁcant differences between
groups were included as covariates in the multivari-
able model (body mass index, diabetes, previous
myocardial infarction, family history of CAD, previ-
ous percutaneous intervention for multivessel dis-
ease, smoking, presentation with an acute coronary
syndrome, number of stents per patient, and type B2
or C lesions). For the DES-level analysis, the consis-
tency of the effect of new-generation DES in patients
with or without CKD was evaluated with a formal
interaction test. We judged p values <0.05 to be sig-
niﬁcant, and all analyses were done with SAS version
9.2 software (SAS Institute, Cary, North Carolina).RESULTS
BASELINE CHARACTERISTICS. Of 10,620 women
included in the pooled dataset and who received a
DES, baseline creatinine level was available for 4,217
(39.7%). Of them, 1,414 had CKD (33.5%). Among
those with CKD, 603 (14.3%) had severe renal
impairment (CrCl <45 ml/min) and 811 (19.2%) had
moderate renal impairment (CrCl 45 to 59 ml/min).
Clinical characteristics according to baseline renal
function are reported in Table 1. Women with
CrCl <45 ml/min were older, had lower body mass
index, and had greater prevalence of diabetes melli-
tus, arterial hypertension, previous MI, and previous
percutaneous or surgical coronary revascularization.
Conversely, they had lower prevalence of family his-
tory of CAD, active smoking, and hypercholesterole-
mia. Angiographic and procedural data are reported
in Table 1. Women with CrCl <45 ml/min had a higher
prevalence of multivessel CAD, moderate or severe
calciﬁcations, and type B2/C lesions and had longer
total stent length.
EFFECT OF RENAL FUNCTION ON 3-YEAR CLINICAL
OUTCOMES. A signiﬁcant stepwise increase in 3-year
rates of MACE (Figure 2A, Online Figure 1) (12.9% vs.
15.8% vs. 26.6%; p < 0.01), all-cause mortality
(Figure 2B) (3.1% vs. 6.4% vs. 16.1%; p < 0.01), cardiac
mortality (3.1% vs. 6.4% vs. 16.1%; p < 0.01), MI (5.2%
vs. 6.3% vs. 10.2%; p < 0.01), and the composite of
death, MI, or stent thrombosis (8.0% vs. 11.1% vs.
22.4%; p < 0.01) was observed in the transition from
normal (CrCl $60 ml/min) to severely impaired renal
function (CrCl <45 ml/min). Conversely, there were
no differences in the rate of TLR at 3 years among
groups (6.4% vs. 6.1% vs. 6.8%; p ¼ 0.77).
Following adjustment for baseline confounders,
severe impairment of renal function (CrCl<45ml/min)
was independently associated with an increased risk
FIGURE 3 2-Year Adverse Events According to Chronic Kidney Disease Status and DES Generation
Kaplan-Meier survival curves for the composite of cardiac death, myocardial infarction (MI), or stent thrombosis (A) and cardiac death (B) at
3 years in women treated with early- or new-generation (Gen) drug-eluting stents according to chronic kidney disease (CKD) status. The
p values are from log-rank test.
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TABLE 3 Adjusted 2-Year Clinical Outcomes Between Early- and New-Generation DES in Women With or Without CKD
No CKD (CrCl $60 ml/min) CKD (CrCl <60 ml/min)
p Value
for Interaction
Early-Generation
DES
New-Generation
DES
Adjusted HR
(95% CI)
Early-Generation
DES
New-Generation
DES
Adjusted HR
(95% CI)
Death 27 (2.0) 30 (2.1) 1.08 (0.61–1.91) 62 (8.3) 51 (7.1) 0.70 (0.47–1.04) 0.29
Cardiac death 15 (1.1) 18 (1.3) 0.99 (0.48–2.04) 42 (5.6) 30 (4.2) 0.58 (0.35–0.97) 0.28
Myocardial infarction 67 (4.9) 64 (4.4) 0.80 (0.54–1.18) 53 (7.1) 44 (6.2) 0.76 (0.49–1.17) 0.76
TLR 74 (5.4) 73 (5.1) 1.23 (0.84–1.80) 35 (4.7) 37 (5.2) 1.36 (0.82–2.25) 0.84
Deﬁnite or probable ST 16 (1.2) 10 (1.4) 0.59 (0.27–1.32) 11 (1.5) 10 (1.4) 0.75 (0.31–1.78) 0.57
Death or MI 88 (6.5) 89 (6.2) 0.92 (0.66–1.29) 102 (13.6) 82 (11.5) 0.72 (0.53–1.00) 0.34
Cardiac death, MI, or ST 79 (5.8) 83 (5.8) 0.88 (0.62–1.25) 83 (11.1) 66 (9.2) 0.70 (0.49–1.00) 0.44
Values are n (%) unless otherwise indicated.
CI ¼ conﬁdence interval; CKD ¼ chronic kidney disease; HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.
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35of MACE (Table 2) (adjusted hazard ratio [adjHR]:
1.56; 95% conﬁdence interval [CI]: 1.23 to 1.98; trend
p < 0.01), all-cause mortality (adjHR: 2.67; 95% CI:
1.85 to 3.85; trend p < 0.01), cardiac mortality (adjHR:
2.75; 95% CI: 1.65 to 4.61; trend p < 0.01), MI (HR:
1.33; 95% CI: 0.90 to 1.97; trend p < 0.01), and the
composite of death, MI, or stent thrombosis (adjHR:
1.85; 95% CI: 1.40 to 2.44; trend p < 0.01) compared
with normal renal function (CrCl $60 ml/min) or
moderate renal impairment (CrCl 45 to 59 ml/min).
Moreover, a trend toward a higher risk of ST was
observed in patients with severely impaired renal
function (adjHR: 1.54; 95% CI: 0.70 to 3.39; trend p ¼
0.05). Conversely, severe renal impairment was not
associated with an increased risk of TLR. Finally,
moderate renal dysfunction (CrCl 45 to 59 ml/min)
was not independently associated with a higher risk
of adverse events compared with normal renal
function.
EARLY- VERSUS NEW-GENERATION DES IN WOMEN
WITH CKD. In women with CKD, at unadjusted
analysis, new-generation DES were associated with
lower 2-year rates of the composite of cardiac death,
MI, or stent thrombosis (Figure 3A) (9.2% vs. 11.1%;
p ¼ 0.002) and cardiac death (Figure 3B) (5.6%
vs. 4.2%; p < 0.0001). Following multivariable
adjustment for baseline confounders (Table 3), use of
new-generation DES in women with CKD was asso-
ciated with a reductions in cardiac death, MI, or ST
(adjHR: 0.70; 95% CI: 0.49 to 1.00), death or MI
(adjHR: 0.72; 95% CI: 0.53 to 1.00), and cardiac death
(adjHR: 0.58; 95% CI: 0.35 to 0.97). The magnitude
and direction of the effect of new-generation DES
use was uniform between patients with or without
CKD, with no evidence of interaction. The effect of
new-generation DES on outcomes was consistent
using a CrCl threshold of <45 ml/min (Online
Table 3).DISCUSSION
To the best of our knowledge, the present report is
the largest to date to examine the effect of CKD and
different DES platforms on long-term risk after PCI
in female randomized trial participants. Our results
demonstrate that: 1) CKD is a common comorbidity
among women undergoing PCI with DES and is
associated with a strong and durable risk for MACE
and mortality; 2) the effect of renal dysfunction on
adverse events is graded, particularly among those
with CrCl <45 ml/min; and 3) compared with early-
generation DES, use of newer-generation DES is
associated with improved safety and efﬁcacy in
women with CKD.
EFFECT OF RENAL FUNCTION ON ADVERSE EVENTS
IN WOMEN. Consistent with previous reports eval-
uating the effect of CKD in cardiovascular disease,
impaired renal function was associated with a
higher risk for MACE and death compared with
preserved renal function (7,8). We observed an in-
ﬂection point for excess risk at levels of CrCl <45
ml/min, similar to a threshold previously reported
in a large population-based sample of U.S. adults
(7). Despite these well-documented associations,
analogous data examining long-term outcomes in
women with CKD across the spectrum of clinical
CAD presentations remain limited. Among ST-
segment elevation MI patients, for example, a
post-hoc analysis of the HORIZONS-AMI (Harmo-
nizing Outcomes With Revascularization and Stents
in Acute Myocardial Infarction) trial showed sub-
stantial and excess thrombotic risk associated with
CKD in both male and female patients. Renal
impairment was not linked with higher rates of TLR
in that report, as is consistent with our results.
Consequently, our ﬁndings, in concert with earlier
observations, highlight the prognostic relevance of
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36renal dysfunction as a strong and robust marker of
excess long-term risk in women undergoing PCI.
Renal-attributable risk is at least partially due to
the higher prevalence of comorbidities that increase
in the transition from normal to severely impaired
renal function (CrCl <45 ml/min). Concordant with
this clinical phenotype, we also showed a greater
burden and complexity of CAD among women with
CrCl <45 ml/min. Nevertheless, the association be-
tween moderate to severe renal dysfunction and
increased MACE risk persisted after adjusting for
baseline imbalances between CKD groups, suggesting
that alternative and independent mechanisms may be
contributory in such patients. Indeed, common risk
factors for both CKD and atherosclerosis, including
advanced age, arterial hypertension, dyslipidemia
and diabetes mellitus, suggest a shared pathophysi-
ological substrate for both conditions, yet do not fully
account for the observed morbidity in female patients
with moderate to severe CKD. Excess risk may also be
attributable to a systemic inﬂammatory state, oxida-
tive stress, and signiﬁcant endothelial dysfunction,
factors that may act in a synergistic manner to
enhance thrombosis (7,10).
Of note, baseline creatinine levels were available in
less than one-half of our entire pooled patient popu-
lation. Given the importance of CKD as a risk factor
for subsequent MACE and mortality, this ﬁnding
emphasizes the importance to measure baseline
creatinine levels in patients undergoing PCI for
optimal risk stratiﬁcation and implementation of
strategies to avoid contrast-induced nephropathy.
NEW-GENERATION DES IN WOMEN WITH CKD.
Compared with early-generation DES, the improved
safety and efﬁcacy of new-generation DES has been
demonstrated in a multitude of RCTs and meta-
analyses (41). In the present study, we shed light on
the relative safety and efﬁcacy of new-generation DES
in women with CKD. Although previous studies sug-
gested an attenuation of beneﬁt of newer-generation
DES in the setting of CKD (6,42), we observed non-
differential reduction in risks for cardiac death, MI,
or ST irrespective of CKD status. Potential mecha-
nisms by which CKD might increase the risk of DES
failure include enhanced propensity for thrombosis,
increased systemic inﬂammation, disturbances in
glucose homeostasis that might affect the patterns
of endothelialization and the burden of neointimal
hyperplastic response, and a milieu of accelerated
atherosclerosis with subsequent development of
neoatherosclerosis within the implanted DES plat-
form. However, newer-generation DES, by optimiza-
tion of biocompatibility, drug-release kinetics,vascular healing, and endothelial coverage, overcome
limitations of early-generation DES and provide
consistent beneﬁts irrespective of renal function (41).
STUDY LIMITATIONS. Although our ﬁndings rely on
individual patient-level, high-quality data from pro-
spective, randomized trials with data monitoring and
event adjudication by clinical event committees,
several limitations have to be disclosed. First, some
trials included in the analysis were performed more
than 1 decade ago, since which time clinical practice
and device technology have changed. To reduce the
trial effect on outcomes, we included trial as a
random effect in our adjusted analyses. Second, pa-
tient populations across trials were heterogeneous;
early trials focused only on stable CAD with simple
lesions, whereas more recent trials included more
complex patient and lesion subsets. Third, the
exclusion of male participants from this study pre-
cludes sex-speciﬁc analysis, limiting the external
validity of our ﬁndings. Fourth, as a post-hoc analysis
of randomized trials, our results are subject to resid-
ual or unmeasured confounding. Fifth, the relatively
low numbers for each early- and new-generation DES
type limits our ability to perform between-stent
comparisons within each renal function category.
Sixth, angiographic follow-up was not available in the
pooled dataset, mitigating our ability to compare
angiographic performances of new-generation DES in
such a high-risk population. Seventh, serum creati-
nine was not available in all study participants
(>10,000 women), rendering our point estimates and
subgroup comparisons less precise. Finally, data on
dual antiplatelet therapy adherence, potency, and
duration were not available, limiting the ﬁndings of
the DES generation-level analysis.
CONCLUSIONS
CKD is a common comorbidity among women with
CAD undergoing percutaneous revascularization
with DES. Impaired renal function is associated
with a strong, dose-dependent effect on the long-
term risk of MACE and mortality. Compared with
early-generation DES, use of newer-generation DES is
associated with consistent and uniform beneﬁts in
women with or without CKD.
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PERSPECTIVES
WHAT IS KNOWN? Previous studies suggested that
CKD attenuates the safety and efﬁcacy of new-generation
DES. The magnitude of this effect in women undergoing
PCI is unknown.
WHAT IS NEW? Among women undergoing PCI with
DES, CKD is a common comorbidity associated with a
strong and independent risk of major adverse events and
mortality. Compared with early-generation DES, new-
generation devices are associated with consistent and
uniform beneﬁts in women with or without CKD.
WHAT IS NEXT? Evaluation of renal function in women
undergoing PCI should be a standard of care for optimal
risk stratiﬁcation and implementation of contrast-induced
nephropathy avoidance strategies.
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